Vanda Pharmaceuticals

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vanda Pharmaceuticals reports mixed Q4 results amid legal challenges and opportunities

Vanda Pharmaceuticals faces financial challenges with declining revenues and HETLIOZ sales, offset by increased cash reserves and positive clinical trial outcomes.
Legal battles and uncertainties add complexity to the company's financial outlook, requiring strategic planning and risk management.
Despite hurdles, opportunities for growth exist through new drug applications, market expansion, and potential partnerships to drive future success.

Vanda Pharmaceuticals reports resilient Q1 performance amidst generic challenges

Vanda Pharmaceuticals delivered a strong performance in Q1 2023, navigating challenges from generic competition while focusing on growth opportunities.
The company's financial results and strategic initiatives position it well for future expansion and innovation in the pharmaceutical industry.
Despite uncertainties surrounding litigation and generic competition, Vanda remains resilient and committed to driving long-term value for stakeholders.

Vanda Pharmaceuticals navigates revenue decline, eyes regulatory approvals for growth

Vanda Pharmaceuticals faced revenue challenges due to generic competition impacting HETLIOZ sales, leading to a revenue decline.
Despite legal uncertainties and revenue setbacks, the company showcased strength in pipeline progress and operational cost management.
Management's confidence in regulatory outcomes and strategic flexibility positions Vanda for potential growth opportunities.

Vanda Pharmaceuticals reports revenue decline but maintains positive net income

Vanda Pharmaceuticals faces revenue challenges with declining total revenues and net product sales in 2023.
Despite this, the company maintains positive net income and focuses on upcoming FDA decisions for growth.
Strong leadership, operational efficiency, and a diversified product portfolio are key strengths for Vanda.
Exploring growth opportunities through FDA decisions, market expansion, and strategic initiatives is crucial for future success.

Vanda Pharmaceuticals reports revenue decline, pursues new treatments amid challenges

Vanda Pharmaceuticals faced revenue declines and net losses in Q4 2023, driven by challenges in product sales and market conditions.
Despite these setbacks, the company is strategically expanding its product portfolio and pursuing new treatments to drive future growth.
Navigating legal battles, generic competition, and market uncertainties will be key focus areas for Vanda in the coming year.

Vanda Pharmaceuticals navigates revenue challenges, eyes growth through strategic initiatives

Vanda Pharmaceuticals faced revenue challenges due to generic competition but remains focused on driving growth through commercial strategies.
The company's psychiatry portfolio expansion and ongoing clinical programs position it well for future market opportunities.
Addressing shareholder activism and evaluating takeover proposals while maintaining operational focus are key challenges ahead.
Engaging with the FDA for product approvals and planning strategic marketing initiatives offer avenues for revenue growth.

Vanda Pharmaceuticals reports revenue growth and strategic expansion plans

Vanda Pharmaceuticals is navigating a mixed financial performance with revenue growth but a net loss in Q2 2024. The company's focus on expanding its commercial organization and advancing clinical development indicates a strategic approach to drive future growth amidst challenges from generic competition.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The biotech had discouraging news to report about one of its pipeline drugs. The FDA declined to approve its application.

Why Vanda Pharmaceuticals Stock Sank by Nearly 6% Today

The company has criticized the FDA for failing to hold advisory committee meetings as well as going against the FDCA.

Vanda Pharmaceuticals decries FDA's rejection of stomach paralysis drug as unjust

Thursday, the FDA declined to approve Vanda Pharmaceuticals Inc.'s VNDA New Drug Application (NDA) of tradipitant for symptoms in gastroparesis, providing Vanda with a Complete Response Letter (CRL).

FDA Strikes Off Vanda Pharmaceuticals' Tradipitant For Stomach Paralysis, Asks For Additional Studies

The U.S. Food and Drug Administration has declined to approve Vanda Pharmaceuticals' drug to treat stomach paralysis symptoms, the company said on Thursday.

U.S. FDA declines to approve Vanda's stomach paralysis drug

WASHINGTON , Sept. 19, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provided an update on its tradipitant development program.

FDA Declines to Approve Vanda's Marketing Application for Tradipitant in Gastroparesis

WASHINGTON , Sept. 11, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the 2024 Cantor Global Healthcare Conference in New York City on Thursday, September 19, 2024.

Vanda Pharmaceuticals Announces Participation in the 2024 Cantor Global Healthcare Conference

WASHINGTON , Sept. 4, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the H.C.

Vanda Pharmaceuticals Announces Participation in the H.C. Wainwright Global Investment Conference

WASHINGTON , Aug. 29, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the Wells Fargo 2024 Healthcare Conference in Boston on Friday, September 6, 2024. A corporate presentation is scheduled for 11:00 a.m.

Vanda Pharmaceuticals Announces Participation in the Wells Fargo 2024 Healthcare Conference

Vanda Pharmaceuticals Inc. received and then refused two takeover bids that were well above current market prices. Vanda currently trades below net cash despite having significant revenue and operations. Vanda has disgruntled shareholders who may find creative ways to maximize shareholder value, despite a recent AGM failing to oust the unpopular Board of Directors and an existing poison pill.

Vanda Pharmaceuticals: I Believe That The Bidding War Is Not Over

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA ) Q2 2024 Earnings Conference Call July 31, 2024 4:30 PM ET Company Participants Kevin Moran - Chief Financial Officer Mihael Polymeropoulos - President, Chief Executive Officer & Chairman of the Board Conference Call Participants Charles Duncan - Cantor Fitzgerald Andrew Tsai - Jefferies Operator Thank you for standing by. My name is Meg, and I will be your conference operator today.

Vanda Pharmaceuticals Inc. (VNDA) Q2 2024 Earnings Call Transcript

Revenues for Q2 2024 were $50.5 million, an increase of 6% compared to Q1 2024 and an increase of 10% compared to Q2 2023 Financial Guidance reinstated for Full Year 2024 Fanapt® approved for the acute treatment of bipolar I disorder; commercial launch initiated in Q3 2024 PONVORY® commercial launch in multiple sclerosis initiated in Q3 2024 Tradipitant NDA review for gastroparesis ongoing; PDUFA date of September 18, 2024 Positive results for tradipitant second Phase III motion sickness study results announced in May 2024; NDA expected to be submitted in Q4 2024 WASHINGTON , July 31, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the second quarter ended June 30, 2024. "2024 has been marked by the achievement of significant clinical development milestones and the expansion of our commercial organization to support the commercialization of Fanapt in bipolar disorder and Ponvory in multiple sclerosis," said Mihael H.

Vanda Pharmaceuticals Reports Second Quarter 2024 Financial Results

Conference Call and Webcast to Follow WASHINGTON , July 26, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the second quarter 2024 on Wednesday, July 31, 2024, after the market closes.   Vanda will host a conference call at 4:30 PM ET on Wednesday, July 31, 2024, during which management will discuss the second quarter 2024 financial results and other corporate activities.

Vanda Pharmaceuticals to Announce Second Quarter 2024 Financial Results on July 31, 2024

WASHINGTON , July 1, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. District Court for the District of Delaware (the "Court") denied the motions for judgment on the pleadings that were filed by Teva Pharmaceuticals USA, Inc. ("Teva") and Apotex Inc. and Apotex Corp. ("Apotex") and ordered that Vanda's HETLIOZ® patent lawsuit may proceed. Vanda brought this suit in December 2022, alleging patent infringement against Teva and Apotex (the "Defendants").

Federal Court Allows Vanda's HETLIOZ® Patent Lawsuit to Proceed against Teva and Apotex

Contract manufacturer Future Pak said on Wednesday it has withdrawn its offer to acquire Vanda Pharmaceuticals , citing non-engagement from the U.S. drugmaker.

Future Pak withdraws offer to buy Vanda Pharmaceuticals

WIXOM, Mich.--(BUSINESS WIRE)--Consistent with the position indicated in its June 13, 2024 letter to Vanda Pharmaceuticals (“Vanda”), Future Pak LLC and its affiliates ("Future Pak") today announced that it is withdrawing its offer to acquire the Company, effective immediately, and will focus on other strategic objectives. This action comes after a continued lack of engagement from Vanda and the receipt of Vanda's rejection of Future Pak's final proposal. About Future Pak Future Pak is a privat.

Future Pak Withdraws Proposal to Purchase Vanda Pharmaceuticals Inc.

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 100 points on Thursday.

Vanda Pharmaceuticals And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Vanda Pharmaceuticals said on Wednesday that it has rejected takeover offers from UK-based Cycle Pharmaceutical and a revised bid from contract manufacturer Future Pak, adding that both offers undervalue the U.S. drugmaker.

Vanda rejects Future Pak and Cycle Pharma's takeover offers

WASHINGTON , June 19, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the Company's Board of Directors (the "Board"), following careful review and consultation with its independent financial and legal advisors, has determined that the unsolicited proposal from Cycle Group Holdings Ltd ("Cycle Group") to acquire Vanda for $8.00 per share in cash and the revised unsolicited proposal from Future Pak, LLC ("FP") to acquire Vanda for $8.50-$9.00 per share in cash plus certain Contingent Value Rights ("CVRs") both substantially undervalue Vanda and are not in the best interests of the Company and its shareholders. Accordingly, the Board has rejected the proposals.

Vanda Pharmaceuticals Board of Directors Determines that Recent Unsolicited Takeover Proposals Are Not in the Best Interests of the Company and its Shareholders

Vanda Pharmaceuticals' portfolio includes FDA-approved Hetlioz for sleep disorders, Fanapt for schizophrenia and bipolar I disorder, and Ponvory for multiple sclerosis. VNDA's upcoming pipeline features milsaperidone and tradipitant, with promising Phase III trials for new indications and long-acting injectables. Acquisition offers from Future Pak and Cycle Pharmaceuticals highlight VNDA's undervaluation and strategic value.

Vanda Pharmaceuticals: Undervalued With Promising Pipeline And Acquisition Interest

The Global Bipolar Disorder Market Size was Valued at USD 5.32 Billion in 2023, the Worldwide Bipolar Disorder Market Size is Expected to Reach USD 6.47 Billion by 2033, according to a research report published by Spherical Insights & Consulting. Companies covered: Bristol Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc, H. Lundbeck A/S, Janssen Pharmaceuticals Inc., Otsuka Holdings Co. Ltd., Pfizer Inc., Sunovion Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Abbott Laboratories, Novartis International AG, Alkermes plc, AbbVie Inc., Merck & Co. Inc., Mylan N.V., Neurocrine Biosciences Inc., Vanda Pharmaceuticals Inc., and Key Others Key Vendors. The Global Bipolar Disorder Market Size was Valued at USD 5.32 Billion in 2023, the Worldwide Bipolar Disorder Market Size is Expected to Reach USD 6.47 Billion by 2033, according to a research report published by Spherical Insights & Consulting. Companies covered: Bristol Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc, H. Lundbeck A/S, Janssen Pharmaceuticals Inc., Otsuka Holdings Co. Ltd., Pfizer Inc., Sunovion Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Abbott Laboratories, Novartis International AG, Alkermes plc, AbbVie Inc., Merck & Co. Inc., Mylan N.V., Neurocrine Biosciences Inc., Vanda Pharmaceuticals Inc., and Key Others Key Vendors.

Global Bipolar Disorder Market Size To Exceed USD 6.47 Billion By 2033 | CAGR Of 1.98%

No Shareholder Action Required at This Time WASHINGTON , June 13, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (Nasdaq: VNDA) today confirmed that it has received a revised unsolicited proposal from Future Pak, LLC ("FP") to acquire Vanda for $8.50-$9.00 per share in cash plus certain Contingent Value Rights. Consistent with its fiduciary duties, and in consultation with its financial and legal advisors, Vanda's Board will carefully review and evaluate the revised, non-binding proposal to determine the course of action that it believes is in the best interests of the Company and its shareholders.

Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future Pak

Contract manufacturer Future Pak said on Thursday it has raised the cash portion of its buyout offer as part of a final attempt to acquire Vanda Pharmaceuticals.

Future Pak raises cash portion of buyout offer for Vanda

WIXOM, Mich.--(BUSINESS WIRE)--Future Pak, LLC and its affiliates ("Future Pak") today announced that it has submitted a final attempt to engage with Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") in a good faith effort to acquire all outstanding shares of Vanda (the “Transaction”). Following the offer announced by Cycle Pharmaceuticals Ltd on June 6, 2024 to acquire Vanda as well as Future Pak's improved offer, it is clear that Vanda's Board should conduct a process to explore strategic.

Future Pak Issues Enhanced and Final Proposal to Acquire Vanda Pharmaceuticals Inc.

ICC Hlds

SAN FRANCISCO--(BUSINESS WIRE)-- #assistivetechnology--CIONIC Unveils Three New Centers of Excellence to Aid Patient Mobility Through the Use of FDA-Cleared Bionic Clothing and Neuromodulation.

CIONIC Unveils Three New Centers of Excellence on the East Coast to Aid Patient Mobility Through the Use of FDA-Cleared Bionic Clothing and Neuromodulation

Vanda (VNDA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

News for Vanda Pharmaceuticals Stock (VNDA)